US20050049692A1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Medical device for reduction of pressure effects of cardiac tricuspid valve regurgitation
Assignee: Medtronic 3F Therapeutics Inc
•
Filing: 2003-09-02
•
Granted: —
•
Expires: 2023-09-02
Abstract
Abstract An elongate valve stent and methods for protecting an upper or a lower body of a patient from high venous pressures comprising a stent member, the stent member comprising a support structure and a tissue valve, wherein the tissue valve is configured to permit fluid flow in one direction and prevent fluid flow in an opposite direction, and means for anchoring the stent member onto surrounding tissue of the superior vena cava or inferior vena cava.
Inventors
- 👤 Michael Numamoto
- 👤 Rodolfo Quijano
- 👤 Hosheng Tu
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 01:52
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/02; A61F2/24; A61F2/2475; A61F2/2412; A61F2/2418; A61F2220/00; A61F2220/0008; A61F2220/0016; A61F2230/00; A61F2230/0002; A61F2230/0028; A61F2230/0054
Claims Analysis
Total Claims: 38
Claim 1
Independent Claim
56 words
1 . An elongate valve stent comprising: a stent member, said stent member comprising a support structure and a tissue valve, wherein said tissue valve is configured to permit fluid flow in one direction and prevent fluid flow in an opposite direction; and means for anchoring said stent member onto surrounding tissue of a blood vessel.
Claim 2
Dependent Claim
56 words
1 . An elongate valve stent comprising: a stent member, said stent member comprising a support structure and a tissue valve, wherein said tissue valve is configured to permit fluid flow in one direction and prevent fluid flow in an opposite direction; and means for anchoring said stent member onto surrounding tissue of a blood vessel.
Claim 3
Dependent Claim
66 words
2 . An elongate valve stent comprising: a stent member, said stent member comprising a support structure and a tissue valve, wherein said tissue valve is configured to permit fluid flow in one direction and prevent fluid flow in an opposite direction; and means for filtering the fluid of a blood vessel, wherein the blood vessel is a superior vena cava or an inferior vena cava.
Claim 4
Dependent Claim
66 words
2 . An elongate valve stent comprising: a stent member, said stent member comprising a support structure and a tissue valve, wherein said tissue valve is configured to permit fluid flow in one direction and prevent fluid flow in an opposite direction; and means for filtering the fluid of a blood vessel, wherein the blood vessel is a superior vena cava or an inferior vena cava.
Claim 5
Dependent Claim
17 words
3 . The elongate valve stent of claim 1 , wherein the blood vessel is a vein.
Claim 6
Dependent Claim
24 words
4 . The elongate valve stent of claim 3 , wherein the blood vessel is a superior vena cava or an inferior vena cava.
Claim 7
Dependent Claim
29 words
5 . The elongate valve stent of claim 1 or 2 , wherein the support structure is collapsibly expandable from a first collapsed position to a second expanded position.
Claim 8
Dependent Claim
23 words
6 . The elongate valve stent of claim 1 or 2 , wherein said support structure of the elongate valve stent is self-expandable.
Claim 9
Dependent Claim
27 words
7 . The elongate valve stent of claim 1 or 2 , wherein said support structure of the elongate valve stent is expandable by an inflatable balloon.
Claim 10
Dependent Claim
83 words
8 . The elongate valve stent of claim 1 or 2 , wherein the support structure of said stent is made of a shape-memory material having a first shape transition temperature of between about 30° C. and 45° C. and a second shape transition temperature of about 5° C. and −10° C., said support structure being collapsibly deformed to below the second shape transition temperature during a stent delivery phase and expanded after delivery in place upon reaching the first shape transition temperature.
Claim 11
Dependent Claim
22 words
9 . The elongate valve stent of claim 1 or 2 , wherein said tissue valve has at least one valve leaflet.
Claim 12
Dependent Claim
18 words
10 . The elongate valve stent of claim 9 , wherein said leaflet is made from a pericardium.
Claim 13
Dependent Claim
29 words
11 . The elongate valve stent of claim 10 , wherein the pericardium is selected from a group consisting of bovine pericardia, equine pericardia, porcine pericardia, and ovine pericardia.
Claim 14
Dependent Claim
37 words
12 . The elongate valve stent of claim 9 , wherein said leaflet is chemically treated by a chemical treating agent selected from a group consisting of glutaraldehyde, formaldehyde, dialdehyde starch, epoxy compounds, genipin, and mixture thereof.
Claim 15
Dependent Claim
43 words
13 . The elongate valve stent of claim 1 or 2 , wherein said tissue valve is a venous valve procured from a group consisting of a bovine jugular vein, an equine jugular vein, a porcine jugular vein, and an ovine jugular vein.
Claim 16
Dependent Claim
20 words
14 . The elongate valve stent of claim 1 or 2 , wherein said tissue valve is a porcine valve.
Claim 17
Dependent Claim
32 words
15 . The elongate valve stent of claim 1 or 2 , wherein said support structure is made of a material selected from a group consisting of stainless steel, Nitinol, and plastics.
Claim 18
Dependent Claim
22 words
16 . The elongate valve stent of claim 1 or 2 , wherein said support structure is coated with a therapeutic agent.
Claim 19
Dependent Claim
39 words
17 . The elongate valve stent of claim 16 , wherein said therapeutic agent is selected from a group consisting of anticoagulants, antithrombogenic agents, anti-proliferative agents, anti-inflammatory agents, antibiotics, stem cells, growth factors, angiogenesis agents, anti-angiogenesis agents, and statins.
Claim 20
Dependent Claim
39 words
18 . The elongate valve stent of claim 1 , wherein said anchoring means comprises at least a hook configured for anchoring said stent member onto surrounding tissue of either a superior vena cava or an inferior vena cava.
Claim 21
Dependent Claim
35 words
19 . The elongate valve stent of claim 2 , wherein said filtering means for filtering the fluid of the blood vessel comprises a filter member mounted at an upstream side of said stent member.
Claim 22
Dependent Claim
129 words
20 . A method of protecting an upper or a lower body of a patient from high venous pressures comprising: providing an elongate valve stent, wherein said stent comprises a stent member with a tissue valve secured to a support structure, wherein the support structure is collapsibly expandable, and anchoring means for anchoring said stent member onto surrounding tissue of a vena cava; passing the elongate valve stent through a blood vessel with the support structure in a collapsed position; deploying the stent to an inferior vena cava or a superior vena cava with the support structure in an expanded shape; and securing the stent by anchoring said stent member onto the surrounding tissue of either the superior vena cava or the inferior vena cava with said anchoring means.
Claim 23
Dependent Claim
129 words
20 . A method of protecting an upper or a lower body of a patient from high venous pressures comprising: providing an elongate valve stent, wherein said stent comprises a stent member with a tissue valve secured to a support structure, wherein the support structure is collapsibly expandable, and anchoring means for anchoring said stent member onto surrounding tissue of a vena cava; passing the elongate valve stent through a blood vessel with the support structure in a collapsed position; deploying the stent to an inferior vena cava or a superior vena cava with the support structure in an expanded shape; and securing the stent by anchoring said stent member onto the surrounding tissue of either the superior vena cava or the inferior vena cava with said anchoring means.
Claim 24
Dependent Claim
33 words
21 . The method of claim 20 , wherein said tissue valve is configured to permit blood flow towards a right atrium of the patient and prevent blood flow in an opposite direction.
Claim 25
Dependent Claim
42 words
22 . The method of claim 20 , wherein the step of passing the elongate valve stent endoluminally is through an incision at a blood vessel selected from a group consisting of a jugular vein, a femoral vein, and a subclavian vein.
Claim 26
Dependent Claim
14 words
23 . The method of claim 20 , wherein the support structure is self-expandable.
Claim 27
Dependent Claim
18 words
24 . The method of claim 20 , wherein the support structure is expandable by an inflatable balloon.
Claim 28
Dependent Claim
73 words
25 . The method of claim 20 , wherein the support structure is made of a shape-memory material having a first shape transition temperature of between about 30° C. and 45° C. and a second shape transition temperature of about 5° C. and −10° C., said support structure being collapsibly deformed to below the second shape transition temperature during delivery and expanded after delivery in place upon reaching the first shape transition temperature.
Claim 29
Dependent Claim
28 words
26 . The method of claim 20 , wherein the support structure is made of a material selected from a group consisting of stainless steel, Nitinol, and plastics.
Claim 30
Dependent Claim
18 words
27 . The method of claim 20 , wherein the support structure is coated with a therapeutic agent.
Claim 31
Dependent Claim
37 words
28 . The method of claim 27 , wherein said therapeutic agent is selected from a group consisting of anticoagulants, antithrombogenic agents, anti-proliferative agents, anti-inflammatory agents, antibiotics, stem cells, growth factors, angiogenesis agents, anti-angiogenesis agents, and statins.
Claim 32
Dependent Claim
18 words
29 . The method of claim 20 , wherein the tissue valve has at least one valve leaflet.
Claim 33
Dependent Claim
16 words
30 . The method of claim 29 , wherein said leaflet is made from a pericardium.
Claim 34
Dependent Claim
31 words
31 . The method of claim 30 , wherein the pericardium is selected from a group consisting of a bovine pericardium, an equine pericardium, a porcine pericardium, and an ovine pericardium.
Claim 35
Dependent Claim
34 words
32 . The method of claim 20 , wherein the tissue valve is chemically treated with a chemical selected from a group consisting of glutaraldehyde, formaldehyde, dialdehyde starch, epoxy compounds, genipin, and mixture thereof.
Claim 36
Dependent Claim
39 words
33 . The method of claim 20 , wherein the tissue valve is a venous valve procured from a group consisting of a bovine jugular vein, an equine jugular vein, a porcine jugular vein, and an ovine jugular vein.
Claim 37
Dependent Claim
16 words
34 . The method of claim 20 , wherein the tissue valve is a porcine valve.
Claim 38
Dependent Claim
23 words
35 . The method of claim 20 , wherein said support structure further comprises filtering means for filtering fluid of the vena cava.
References Cited (Backward Citations)
US6610085B1
Cited
US4806595A
Cited
US5997573A
Cited
US5824061A
Cited
US5607465A
Cited
US6383193B1
Cited
US6451025B1
Cited
US5855601A
Cited
US6608040B1
Cited
US5957949A
Cited
US6007575A
Cited
US5954766A
Cited
US6299637B1
Cited
US6517573B1
Cited
US6676698B2
Cited
US6503272B2
Cited
US20040260390A1
Cited
US20030135255A1
Cited
US20030163194A1
Cited
US20040206363A1
Cited
US20040210306A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.